4.6 Review

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Journal

VIRUSES-BASEL
Volume 7, Issue 12, Pages 6291-6312

Publisher

MDPI
DOI: 10.3390/v7122938

Keywords

oncolytic virus; immunotherapy; reovirus; vaccinia; HSV; clinical trials

Categories

Funding

  1. Yorkshire Cancer Research
  2. Cancer Research UK
  3. Cancer Research UK [13244] Funding Source: researchfish
  4. National Institute for Health Research [ACF-2015-02-003] Funding Source: researchfish

Ask authors/readers for more resources

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available